PMEF
SRNE

Point72 Middle East FZE’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Point72 Middle East FZE’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-130,765
Closed -$116K – 2388
2022
Q4 		$116K Buy
+130,765
New +$173K 0.01% 1224

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Point72 Middle East FZE's SRNE Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 130,765 shares — an estimated $116K sold.

Point72 Middle East FZE first reported a position in SRNE in Q4 2022 and held it in 1 quarter. The position peaked at $116K in Q4 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 130,765 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $116K.
  • Point72 Middle East FZE first reported a position in Sorrento Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Sorrento Therapeutics, Inc. position peaked at $116K in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.